These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9116933)

  • 1. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
    Kornowski R; Eldor A; Werber MM; Ezov N; Zwang E; Nimrod A; Chernine A; Finkelstein A; Panet A; Laniado S; Keren G
    Coron Artery Dis; 1996 Dec; 7(12):903-9. PubMed ID: 9116933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
    Mellott MJ; Holahan MA; Lynch JJ; Vlasuk GP; Dunwiddie CT
    Circ Res; 1992 Jun; 70(6):1152-60. PubMed ID: 1576736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
    Nicolini FA; Lee P; Malycky JL; Lefkovits J; Kottke-Marchant K; Plow EF; Topol EJ
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Blood; 1990 Nov; 76(10):2030-6. PubMed ID: 2122919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
    Antman EM
    Circulation; 1996 Sep; 94(5):911-21. PubMed ID: 8790025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
    Schneider J
    Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reocclusion after thrombolysis: a problem solved by hirudin?
    Rübsamen K; Eschenfelder V
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):97-100. PubMed ID: 1773004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I; Finkle CD; Winocour PD
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.
    Klement P; Borm A; Hirsh J; Maraganore J; Wilson G; Weitz J
    Thromb Haemost; 1992 Jul; 68(1):64-8. PubMed ID: 1514174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
    Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K; Hornberger W
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.